Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca Likely To Reduce Its Contract Sales Force, PDI Says

This article was originally published in The Pink Sheet Daily

Executive Summary

The sales and marketing staffing firm currently contracts 800 reps to AstraZeneca.

You may also be interested in...



Sanofi-Aventis Ends PDI Sales Contract

Big pharma is “reevaluating its commercial model,” PDI said in reaction to losing the $18 mil. to $20 mil. Sanofi contract.

Sanofi-Aventis Ends PDI Sales Contract

Big pharma is “reevaluating its commercial model,” PDI said in reaction to losing the $18 mil. to $20 mil. Sanofi contract.

PDI Reducing Reliance On Top Pharma Clients

Contract sales organization’s top four clients – AstraZeneca, GSK, Novartis and Sanofi-Aventis – will represent 59% of 2005 revenue, versus 81% in 2004, PDI says. Contracts with three of the four companies have been renewed.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS063669

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel